SAN FRANCISCO – In sports, championship teams in one year invariably find it difficult to repeat their performances the following year. The biotech sector is experiencing a similar situation. While U.S. and European biotech companies established new financial performance records last year, the financial and business statistics six months into the current year indicate that the industry is on pace for a less than stellar 2016.